Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Dopanergic agonists and schizophrenia].

J F Pidgeon, M A Wolf

    Psychiatric Journal of the University of Ottawa : Revue De Psychiatrie De L'Universite D'Ottawa
    |November 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Revolutionizing medical education: Surgery takes the lead in virtual reality research.

    Surgery open science·2025
    Same author

    Comprehensive Analysis of Scientific Output in Hip and Knee Arthroscopy.

    Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca·2023
    Same author

    Memory impairment in schizophrenia: a study using event-related potentials in implicit and explicit tasks.

    Psychiatry research·2001
    Same author

    Neuropsychological impairments in the syndromes of schizophrenia: a comparison between different dimensional models.

    Brain and cognition·2001
    Same author

    Pigmented conjunctival squamous cell carcinoma simulating a conjunctival melanoma.

    American journal of ophthalmology·2001
    Same author

    Chiasmopathy?

    Survey of ophthalmology·2000

    Dopamine agonists like l-DOPA and bromocriptine show potential for treating schizophrenia, particularly for chronic cases where antipsychotics are ineffective. These drugs may help by modulating the dopamine system, addressing both positive and negative symptoms.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Context:

    • Dopamine (a neurotransmitter) acts via D1 and D2 receptors in the central nervous system.
    • Schizophrenia symptoms may involve dopaminergic hyperactivity (positive symptoms) and structural damage (negative symptoms).
    • Current antipsychotics, which are antidopaminergic, are often ineffective in chronic schizophrenia patients.

    Purpose:

    • To explore the efficacy of dopamine agonists in treating schizophrenia.
    • To investigate if dopamine agonists can desensitize the dopaminergic system or inhibit it via autoreceptors.
    • To examine the hypothesis that reduced frontal cortical dopamine contributes to schizophrenia symptoms and if agonists can enhance this activity.

    Summary:

    • Several dopamine agonists (apomorphine, N-n-propylnorapomorphine, l-DOPA, bromocriptine) have been tested in schizophrenic patients.

    Related Experiment Videos

  • The goal was to modulate the dopaminergic system, either through desensitization or presynaptic inhibition.
  • l-DOPA and bromocriptine emerged as potentially effective treatments.

    • Impact:

    • Identifies l-DOPA and bromocriptine as promising dopamine agonist therapies for schizophrenia.
    • Suggests a potential therapeutic avenue for chronic schizophrenia cases resistant to conventional antipsychotics.
    • Highlights the complex role of dopamine in schizophrenia pathophysiology and treatment.